1995

Received investment from the National Development Fund, Executive Yuan, becoming the first government-supported flagship biopharmaceutical company.

1997

Acquired the Original Bristol-Myers Squibb GMP facility, established the clinical trial department, and introduced CRO services.

2000

Completed Phase III clinical trials for Prestara™, a treatment for SLE, and submitted a New Drug Application (NDA) to the US FDA. Received an “Approvable Letter” from the US FDA in 2002.

2001

Collaborated with Roche to develop and manufacture the antiviral drug Ribavirin.

2003

Launched new drugs: “Genetaxyl” (paclitaxel injection) and “Urotrol” (urinary incontinence treatment).

Listed on the Emerging Stock Market (OTC), breaking even in the first year.

2004

Licensed Tanabe in Japan and Yuhan in Korea to develop Prestara™, receiving upfront licensing fees.

2008

Collaborated with the National Health Research Institutes to jointly develop the anti-diabetes drug DBPR108. Granted market authorization to CSPC Pharmaceutical Group in China in 2012.

2009

Signed a contract manufacturing agreement with Taiwan’s Daiichi Sankyo.

2010

Factory passed Department of Health PIC-S/GMP certification. Approved for the manufacture of sterile ophthalmic solutions in 2014.。

2012

Listed on the Taipei Exchange (TPEx) (stock code: 4130).

2013

Invested in SyneuRx. Assisted CMC in completing SND11 and SND13 (2014) IND filings for the US, entering Phase II/III clinical trials.

Invested in Reber Genetics (stock code: 6479) and THEVAX, acquiring joint development rights for the HPV Vx Chinese market.

2014

Phase II clinical results of PMR met expectations. Licensed to Otsuka Pharmaceuticals in Asia-Pacific for joint development.

Granpatch entered registration clinical trials.

2015

Colon cleanser Bowklean approved by TFDA. PMR entered Phase III clinical trials.

Invested in US cell immunotherapy company Medeor.

2016

Invested in NaviFUS, using non-invasive focused ultrasound to temporarily open the blood-brain barrier, providing treatment options for CNS-related diseases.

2017

Invested in Soleno, developing a new drug for Prader-Willi Syndrome (PWS). Invested in GenVax, developing distinctive new drug formulations.

PMR completed US IND application and initiated human trials in the US.

2018

Received TFDA approval for Mycocep, a new drug for lupus nephritis.

2019

PMR completed pivotal clinical trials in the US.

Co-invested with NaviFUS in GNI, launching the NF02 innovative medical device project for Alzheimer’s disease treatment in Melbourne, Australia.

2020

PMR completed US Pre-NDA meeting and GV17 Pre-IND meeting application.

The new drug DBPR108 for the treatment of diabetes has entered the third phase of clinical trials in mainland China.

PMR obtained a patent in mainland China.

2022

The new drug GX17 was developed for the treatment of “antiphospholipid syndrome (APS)” indications. It passed review by the US FDA and was approved for the first human clinical trial.